Most Active InvestorsFind investorsPricing
Start for free
Start for free
AC

Acuta Capital Partners

North America, California, United States, Belmont

Description

Acuta Capital Partners is a venture capital firm.

Investor Profile

Acuta Capital Partners has backed more than 22 startups, with 3 new investments in the last 12 months alone. The firm has led 2 rounds, about 9% of its total and boasts 17 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Series B, Series C rounds (top funding stages).
  • Majority of deals are located in United States, Ireland.
  • Strong thematic focus on Biotechnology, Health Care, Biopharma.

Stage Focus

  • Post Ipo Equity (64%)
  • Series B (18%)
  • Series C (14%)
  • Series Unknown (5%)

Country Focus

  • United States (91%)
  • Ireland (9%)

Industry Focus

  • Biotechnology
  • Health Care
  • Biopharma
  • Life Science
  • Oncology
  • Therapeutics
  • Pharmaceutical
  • Medical Device
  • Manufacturing
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Acuta Capital Partners frequently co-invest with?

Surveyor Capital
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 6
CA
Cormorant Asset Management
North America, Massachusetts, United States, Boston
Co-Investments: 6
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners
North America, California, United States, Palo Alto
Co-Investments: 9
RTW Investments
RTW Investments
North America, New York, United States, New York
Co-Investments: 6
RA Capital Management
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 10
KC
Co-Investments: 6
Avoro Capital Advisors
Avoro Capital Advisors
North America, New York, United States, New York
Co-Investments: 6
Vivo Capital
Vivo Capital
North America, California, United States, Palo Alto
Co-Investments: 8
Logos Capital
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 10
Janus Henderson Investors
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 5

What are some of recent deals done by Acuta Capital Partners?

Surrozen

South San Francisco, California, United States

Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.

BiotechnologyEmergency MedicineHealth Care
Post Ipo EquityMar 24, 2025
Amount Raised: $175,000,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityMar 4, 2025
Amount Raised: $100,000,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityDec 20, 2024
Amount Raised: $100,000,000
Enliven Therapeutics

Boulder, Colorado, United States

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

BiotechnologyLife ScienceOncologyTherapeutics
Post Ipo EquityMar 19, 2024
Amount Raised: $90,000,000
Ocular Therapeutix

Bedford, Massachusetts, United States

Ocular Therapeutix develops and commercializes ophthalmic therapeutic products by using hydrogel technology.

BiotechnologyHealth CareMedical Device
Post Ipo EquityFeb 22, 2024
Amount Raised: $325,000,000
Tourmaline Bio

New York, New York, United States

Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve and prevent immune diseases.

BiotechnologyClinical TrialsTherapeutics
Post Ipo EquityOct 19, 2023
Amount Raised: $75,000,000
Taysha Gene Therapies

Dallas, Texas, United States

Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.

BiotechnologyGeneticsLife Science
Post Ipo EquityAug 14, 2023
Amount Raised: $150,000,000
BioAtla

San Diego, California, United States

BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform.

BiotechnologyHealth CareMedical
Post Ipo EquityNov 4, 2022
Amount Raised: $65,000,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquitySep 22, 2022
Amount Raised: $72,500,000
Ventyx Biosciences

Encinitas, California, United States

Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.

BiopharmaBiotechnology
Post Ipo EquitySep 19, 2022
Amount Raised: $176,600,000
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Most Active Investors Find InvestorsNewsletterPricing

Free tools

Pre-Money and Post-Money Valuation Calculator